Fusion Pharmaceuticals (FUSN)
FUSN
Oncology
BiotechSign Signal Grade
F
Signal Grade
24.4/100 composite signal score
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Insider Buying
0
Publications
100
Clinical Activity
38
Pipeline Overview
- Therapeutic Focus
- Oncologysrc
Clinical Trial Activity
3
Clinical Trials
(ClinicalTrials.gov aggregate)
(ClinicalTrials.gov aggregate)
3 Phase 2
Trial Phase Breakdown
2
PubMed Publications
0
Catalyst Records
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Recent News & SEC Filings
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Multimodal MRI fusion and three-dimensional reconstruction for preoperative assessment of neurovascular compression in trigeminal neuralgia: A retrospective study. — Neurosurg Rev 2026 Oct 13 PMID 42867713
- Generalized Eruptive Histiocytosis With a GAB2::BRAF Fusion in a Child: A Targetable Driver of Undefined Prognostic Weight. — Pediatr Blood Cancer 2026 Oct 10 PMID 42858102
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Fusion Pharmaceuticals.
Full FUSN Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.